Toll-Like Receptor 4 and Inflammatory Micro-Environment of Pancreatic Islets in Type-2 Diabetes Mellitus: A Therapeutic Perspective

References

• IDF Diabetes atlas, 9th edn. International Diabetes Federation. Available from: https://diabetesatlas.org/en/. Accessed June 4, 2020.
   Google Scholar
• West AP, Koblansky AA, Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol. 2006;22:409–437. doi:10.1146/annurev.cellbio.21.122303.115827
   PubMed Web of Science ®Google Scholar
• Garibotto G, Carta A, Picciotto D, Viazzi F, Verzola D. Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy. J Nephrol. 2017;30(6):719–727. doi:10.1007/s40620-017-0432-8
   PubMed Web of Science ®Google Scholar
• Imler JL, Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol. 2001;11(7):304–311. doi:10.1016/s0962-8924(01)02004-9
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394–397. doi:10.1038/41131
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015;109:1–10. doi:10.1002/0471142735.im1412s109
   Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511. doi:10.1038/nri1391
   PubMed Web of Science ®Google Scholar
• Brodsky I, Medzhitov R. Two modes of ligand recognition by TLRs. Cell. 2007;130(6):979–981. doi:10.1016/j.cell.2007.09.009
   PubMedGoogle Scholar
• Bell JK, Botos I, Hall PR, et al. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci U S A. 2005;102(31):10976–10980. doi:10.1073/pnas.0505077102
   PubMed Web of Science ®Google Scholar
• Choe J, Kelker MS, Wilson IA. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science. 2005;309(5734):581–585. doi:10.1126/science.1115253
   PubMed Web of Science ®Google Scholar
• Kim HM, Park BS, Kim JI, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130(5):906–917. doi:10.1016/j.cell.2007.08.002
   PubMed Web of Science ®Google Scholar
• Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007;130(6):1071–1082. doi:10.1016/j.cell.2007.09.008
   PubMed Web of Science ®Google Scholar
• Kang JY, Nan X, Jin MS, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity. 2009;31(6):873–884. doi:10.1016/j.immuni.2009.09.018
   PubMed Web of Science ®Google Scholar
• Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science. 2008;320(5874):379–381. doi:10.1126/science.1155406
   PubMed Web of Science ®Google Scholar
• Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458(7242):1191–1195. doi:10.1038/nature07830
   PubMed Web of Science ®Google Scholar
• Yoon SI, Kurnasov O, Natarajan V, et al. Structural basis of TLR5-flagellin recognition and signaling. Science. 2012;335(6070):859–864. doi:10.1126/science.1215584
   PubMed Web of Science ®Google Scholar
• Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science. 2013;339(6126):1426–1429. doi:10.1126/science.1229159
   PubMed Web of Science ®Google Scholar
• Ohto U, Shibata T, Tanji H, et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature. 2015;520(7549):702–705. doi:10.1038/nature14138
   PubMed Web of Science ®Google Scholar
• Song W, Wang J, Han Z, et al. Structural basis for specific recognition of single-stranded RNA by Toll-like receptor 13. Nat Struct Mol Biol. 2015;22(10):782–787. doi:10.1038/nsmb.3080
   PubMedGoogle Scholar
• Nyman T, Stenmark P, Flodin S, Johansson I, Hammarström M, Nordlund P. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biol Chem. 2008;283(18):11861–11865. doi:10.1074/jbc.C800001200
   PubMed Web of Science ®Google Scholar
• Xu Y, Tao X, Shen B, et al. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature. 2000;408(6808):111–115. doi:10.1038/35040600
   PubMed Web of Science ®Google Scholar
• Tao X, Xu Y, Zheng Y, Beg AA, Tong L. An extensively associated dimer in the structure of the C713S mutant of the TIR domain of human TLR2. Biochem Biophys Res Commun. 2002;299(2):216–221. doi:10.1016/s0006-291x(02)02581-0
   PubMedGoogle Scholar
• Matsushima N, Tanaka T, Enkhbayar P, et al. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. BMC Genom. 2007;8:124. doi:10.1186/1471-2164-8-124
   PubMed Web of Science ®Google Scholar
• Kajava AV. Structural diversity of leucine-rich repeat proteins. J Mol Biol. 1998;277(3):519–527. doi:10.1006/jmbi.1998.1643
   PubMedGoogle Scholar
• Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol. 2001;11(6):725–732. doi:10.1016/s0959-440x(01)00266-4
   PubMed Web of Science ®Google Scholar
• Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem. 2007;76:141–165. doi:10.1146/annurev.biochem.76.060305.151318
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282(5396):2085–2088. doi:10.1126/science.282.5396.2085
   PubMed Web of Science ®Google Scholar
• Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999;189(11):1777–1782. doi:10.1084/jem.189.11.1777
   PubMed Web of Science ®Google Scholar
• Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999;11(1):115–122. doi:10.1016/s1074-7613(00)80086-2
   PubMed Web of Science ®Google Scholar
• Laird MH, Rhee SH, Perkins DJ, et al. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol. 2009;85(6):966–977. doi:10.1189/jlb.1208763
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16(1):3–9. doi:10.1016/j.smim.2003.10.003
   PubMed Web of Science ®Google Scholar
• Delaney JR, Mlodzik M. TGF-beta activated kinase-1: new insights into the diverse roles of TAK1 in development and immunity. Cell Cycle (Georgetown, Tex). 2006;5(24):2852–2855. doi:10.4161/cc.5.24.3558
   PubMed Web of Science ®Google Scholar
• Saha RN, Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal. 2006;8(5–6):929–947. doi:10.1089/ars.2006.8.929
   PubMed Web of Science ®Google Scholar
• Kawai T, Takeuchi O, Fujita T, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol. 2001;167(10):5887–5894. doi:10.4049/jimmunol.167.10.5887
   PubMed Web of Science ®Google Scholar
• Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev. 2009;59(2):278–292. doi:10.1016/j.brainresrev.2008.09.001
   PubMedGoogle Scholar
• Chuang TH, Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol. 2004;5(5):495–502. doi:10.1038/ni1066
   PubMedGoogle Scholar
• Divanovic S, Trompette A, Atabani SF, et al. Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. J Endotoxin Res. 2005;11(6):363–368. doi:10.1179/096805105X67300
   PubMedGoogle Scholar
• Hu X, Yu Y, Eugene Chin Y, Xia Q. The role of acetylation in TLR4-mediated innate immune responses. Immunol Cell Biol. 2013;91(10):611–614. doi:10.1038/icb.2013.56
   PubMed Web of Science ®Google Scholar
• Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia. 1995;38(8):992–997. doi:10.1007/BF00400591
   PubMedGoogle Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846. doi:10.1038/nature05482
   PubMed Web of Science ®Google Scholar
• Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol. 2000;24(3):297–302. doi:10.1677/jme.0.0240297
   PubMed Web of Science ®Google Scholar
• Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell. 1998;92(5):593–596. doi:10.1016/S0092-8674(00)81125-3
   PubMed Web of Science ®Google Scholar
• Robertson RP, Harmon J, Tran POT, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(Suppl 1):S119–S124. doi:10.2337/diabetes.53.2007.S119
   PubMed Web of Science ®Google Scholar
• Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16–S21. doi:10.2337/diabetes.53.suppl_3.S16
   PubMed Web of Science ®Google Scholar
• Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116(7):1802–1812. doi:10.1172/JCI29103
   PubMed Web of Science ®Google Scholar
• Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004;89(8):3629–3643. doi:10.1210/jc.2004-0405
   PubMed Web of Science ®Google Scholar
• Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes. 2002;51(Suppl 3):S455–S461. doi:10.2337/diabetes.51.2007.S455
   PubMedGoogle Scholar
• Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8(12):923–934. doi:10.1038/nri2449
   PubMed Web of Science ®Google Scholar
• Donath MY, Størling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med. 2003;81(8):455–470. doi:10.1007/s00109-003-0450-y
   PubMed Web of Science ®Google Scholar
• Ehses JA, Ellingsgaard H, Böni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. Arch Physiol Biochem. 2009;115(4):240–247. doi:10.1080/13813450903025879
   PubMedGoogle Scholar
• Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1β production and β-cell dysfunction. Diabetes. 2014;63(5):1698–1711. doi:10.2337/db13-0863
   PubMed Web of Science ®Google Scholar
• Westwell-Roper C, Dai DL, Soukhatcheva G, et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011;187(5):2755–2765. doi:10.4049/jimmunol.1002854
   PubMed Web of Science ®Google Scholar
• Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11(10):897–904. doi:10.1038/ni.1935
   PubMed Web of Science ®Google Scholar
• Jourdan T, Godlewski G, Cinar R, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med. 2013;19(9):1132–1140. doi:10.1038/nm.3265
   PubMed Web of Science ®Google Scholar
• Oslowski CM, Hara T, O’Sullivan-Murphy B, et al. Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab. 2012;16(2):265–273. doi:10.1016/j.cmet.2012.07.005
   PubMed Web of Science ®Google Scholar
• Lerner AG, Upton J-P, Praveen PVK, et al. IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab. 2012;16(2):250–264. doi:10.1016/j.cmet.2012.07.007
   PubMed Web of Science ®Google Scholar
• Ling PR, Smith RJ, Bistrian BR. Acute effects of hyperglycemia and hyperinsulinemia on hepatic oxidative stress and the systemic inflammatory response in rats. Crit Care Med. 2007;35(2):555–560. doi:10.1097/01.Ccm.0000253310.02180.C2
   PubMed Web of Science ®Google Scholar
• Apostolova N, Garcia-Bou R, Hernandez-Mijares A, Herance R, Rocha M, Victor VM. Mitochondrial antioxidants alleviate oxidative and nitrosative stress in a cellular model of sepsis. Pharm Res. 2011;28(11):2910–2919. doi:10.1007/s11095-011-0528-0
   PubMed Web of Science ®Google Scholar
• Lu H, Koshkin V, Allister EM, Gyulkhandanyan AV, Wheeler MB. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes. 2010;59(2):448–459. doi:10.2337/db09-0129
   PubMedGoogle Scholar
• Armann B, Hanson MS, Hatch E, Steffen A, Fernandez LA. Quantification of basal and stimulated ROS levels as predictors of islet potency and function. Am J Transpl. 2007;7(1):38–47. doi:10.1111/j.1600-6143.2006.01577.x
   PubMedGoogle Scholar
• Duprez J, Roma LP, Close AF, Jonas JC, Nadal A. Protective antioxidant and antiapoptotic effects of ZnCl2 in rat pancreatic islets cultured in low and high glucose concentrations. PLoS One. 2012;7(10):e46831. doi:10.1371/journal.pone.0046831
   PubMedGoogle Scholar
• Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol. 2013;48(1):190–204. doi:10.1007/s12035-013-8425-7
   PubMed Web of Science ®Google Scholar
• Maedler K, Fontana A, Ris F. FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication. Proc Natl Acad Sci USA. 2002;99:8236–8241. doi:10.1073/pnas.122686299
   PubMed Web of Science ®Google Scholar
• Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007;56(9):2356–2370. doi:10.2337/db06-1650
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. Islet-associated macrophages in type 2 diabetes. Diabetologia. 2009;52(8):1686–1688. doi:10.1007/s00125-009-1410-z
   PubMed Web of Science ®Google Scholar
• Butcher MJ, Hallinger D, Garcia E, et al. Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes. Diabetologia. 2014;57(3):491–501. doi:10.1007/s00125-013-3116-5
   PubMed Web of Science ®Google Scholar
• Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008;93(10):4065–4074. doi:10.1210/jc.2008-0396
   PubMed Web of Science ®Google Scholar
• Kitamura T. The role of FOXO1 in beta-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol. 2013;9(10):615–623. doi:10.1038/nrendo.2013.157
   PubMed Web of Science ®Google Scholar
• Guest CB, Park MJ, Johnson DR, Freund GG. The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci. 2008;13:5187–5194. doi:10.2741/3074
   PubMed Web of Science ®Google Scholar
• Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42–47. doi:10.1161/01.cir.102.1.42
   PubMed Web of Science ®Google Scholar
• Navarro JF, Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. ScientificWorldJournal. 2006;6:908–917. doi:10.1100/tsw.2006.179
   PubMedGoogle Scholar
• Garay-Malpartida HM, Mourao RF, Mantovani M, Santos IA, Sogayar MC, Goldberg AC. Toll-like receptor 4 (TLR4) expression in human and murine pancreatic beta-cells affects cell viability and insulin homeostasis. BMC Immunol. 2011;12:18. doi:10.1186/1471-2172-12-18
   PubMed Web of Science ®Google Scholar
• Gupta S, Maratha A, Siednienko J, et al. Analysis of inflammatory cytokine and TLR expression levels in Type 2 Diabetes with complications. Sci Rep. 2017;7(1):7633. doi:10.1038/s41598-017-07230-8
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010;33(4):861–868. doi:10.2337/dc09-1799
   PubMed Web of Science ®Google Scholar
• Sepehri Z, Kiani Z, Nasiri AA, et al. Human Toll like receptor 4 gene expression of PBMCs in diabetes mellitus type 2 patients. Cell Mol Biol (Noisy-Le-Grand). 2015;61(3):92–95.
   PubMedGoogle Scholar
• Ahmad R, Al-Mass A, Atizado V, et al. Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. J Inflamm (Lond). 2012;9(1):48. doi:10.1186/1476-9255-9-48
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes. 2008;57(11):3090–3098. doi:10.2337/db08-0564
   PubMed Web of Science ®Google Scholar
• Sindhu S, Akhter N, Kochumon S, et al. Increased expression of the innate immune receptor TLR10 in obesity and type-2 diabetes: association with ROS-mediated oxidative stress. Cell Physiol Biochem. 2018;45(2):572–590. doi:10.1159/000487034
   PubMedGoogle Scholar
• Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105(10):1158–1161. doi:10.1161/circ.105.10.1158
   PubMed Web of Science ®Google Scholar
• Bobryshev YV, Lord RS. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res. 1995;29(5):689–696. doi:10.1016/S0008-6363(96)88642-1
   PubMedGoogle Scholar
• Stoll LL, Denning GM, Li WG, et al. Regulation of endotoxin-induced proinflammatory activation in human coronary artery cells: expression of functional membrane-bound CD14 by human coronary artery smooth muscle cells. J Immunol. 2004;173(2):1336–1343. doi:10.4049/jimmunol.173.2.1336
   PubMed Web of Science ®Google Scholar
• Vink A, Schoneveld AH, van der Meer JJ, et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation. 2002;106(15):1985–1990. doi:10.1161/01.cir.0000032146.75113.ee
   PubMedGoogle Scholar
• Li H, Sun B. Toll-like receptor 4 in atherosclerosis. J Cell Mol Med. 2007;11(1):88–95. doi:10.1111/j.1582-4934.2007.00011.x
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–1808. doi:10.1172/jci19246
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830. doi:10.1172/jci19451
   PubMed Web of Science ®Google Scholar
• Clément K, Viguerie N, Poitou C, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J. 2004;18(14):1657–1669. doi:10.1096/fj.04-2204com
   PubMedGoogle Scholar
• Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y, Ogawa Y. Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun. 2007;354(1):45–49. doi:10.1016/j.bbrc.2006.12.190
   PubMed Web of Science ®Google Scholar
• Shi L, Kishore R, McMullen MR, Nagy LE. Lipopolysaccharide stimulation of ERK1/2 increases TNF-alpha production via Egr-1. Am J Physiol Cell Physiol. 2002;282(6):C1205–C1211. doi:10.1152/ajpcell.00511.2001
   PubMed Web of Science ®Google Scholar
• Poggi M, Bastelica D, Gual P, et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia. 2007;50(6):1267–1276. doi:10.1007/s00125-007-0654-8
   PubMed Web of Science ®Google Scholar
• Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007;56(8):1986–1998. doi:10.2337/db06-1595
   PubMed Web of Science ®Google Scholar
• Saberi M, Woods NB, de Luca C, et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 2009;10(5):419–429. doi:10.1016/j.cmet.2009.09.006
   PubMed Web of Science ®Google Scholar
• Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care. 2009;32(12):2281–2287. doi:10.2337/dc09-0979
   PubMed Web of Science ®Google Scholar
• Harte AL, Varma MC, Tripathi G, et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care. 2012;35(2):375–382. doi:10.2337/dc11-1593
   PubMed Web of Science ®Google Scholar
• van der Crabben SN, Blümer RME, Stegenga ME, et al. Early endotoxemia increases peripheral and hepatic insulin sensitivity in healthy humans. J Clin Endocrinol Metab. 2009;94(2):463–468. doi:10.1210/jc.2008-0761
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol. 2001;1(4):625–635. doi:10.1016/S1567-5769(01)00010-8
   PubMedGoogle Scholar
• Garate I, Garcia-Bueno B, Madrigal JL, et al. Stress-induced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol Psychiatry. 2013;73(1):32–43. doi:10.1016/j.biopsych.2012.07.005
   PubMedGoogle Scholar
• Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR. Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology. 2004;112(3):428–436. doi:10.1111/j.1365-2567.2004.01898.x
   PubMed Web of Science ®Google Scholar
• Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–3025. doi:10.1172/JCI28898
   PubMed Web of Science ®Google Scholar
• Shen X, Yang L, Yan S, et al. Fetuin A promotes lipotoxicity in beta cells through the TLR4 signaling pathway and the role of pioglitazone in anti-lipotoxicity. Mol Cell Endocrinol. 2015;412:1–11. doi:10.1016/j.mce.2015.05.014
   PubMedGoogle Scholar
• Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18(8):1279–1285. doi:10.1038/nm.2851
   PubMed Web of Science ®Google Scholar
• Wang X, Ge QM, Bian F, Dong Y, Huang CM. Inhibition of TLR4 protects rat islets against lipopolysaccharide-induced dysfunction. Mol Med Rep. 2017;15(2):805–812. doi:10.3892/mmr.2016.6097
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhang X, Li Y, Jin J, Huang Y. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J Endocrinol. 2013;216(1):61–71. doi:10.1530/JOE-12-0338
   PubMed Web of Science ®Google Scholar
• Perrin-Cocon L, Aublin-Gex A, Sestito SE, et al. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep. 2017;7:40791. doi:10.1038/srep40791
   PubMed Web of Science ®Google Scholar
• Cighetti R, Ciaramelli C, Sestito SE, et al. Modulation of CD14 and TLR4.MD-2 activities by a synthetic lipid A mimetic. Chembiochem. 2014;15(2):250–258. doi:10.1002/cbic.201300588
   PubMedGoogle Scholar
• Hu L, Yang H, Ai M, Jiang S. Inhibition of TLR4 alleviates the inflammation and apoptosis of retinal ganglion cells in high glucose. Graefes Arch Clin Exp Ophthalmol. 2017;255(11):2199–2210. doi:10.1007/s00417-017-3772-0
   PubMedGoogle Scholar
• Lu Z, Zhang X, Li Y, Lopes-Virella MF, Huang Y. TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes. Immunobiology. 2015;220(11):1246–1254. doi:10.1016/j.imbio.2015.06.016
   PubMed Web of Science ®Google Scholar
• Foresto-Neto O, Albino AH, Arias SCA, et al. NF-kappaB system is chronically activated and promotes glomerular injury in experimental type 1 diabetic kidney disease. Front Physiol. 2020;11:84. doi:10.3389/fphys.2020.00084
   PubMedGoogle Scholar
• Yuan S, Liu X, Zhu X, et al. The role of TLR4 on PGC-1alpha-mediated oxidative stress in tubular cell in diabetic kidney disease. Oxid Med Cell Longev. 2018;2018:6296802. doi:10.1155/2018/6296802
   PubMed Web of Science ®Google Scholar
• Wu C, Lv C, Chen F, Ma X, Shao Y, Wang Q. The function of miR-199a-5p/Klotho regulating TLR4/NF-kappaB p65/NGAL pathways in rat mesangial cells cultured with high glucose and the mechanism. Mol Cell Endocrinol. 2015;417:84–93. doi:10.1016/j.mce.2015.09.024
   PubMed Web of Science ®Google Scholar
• Liu P, Li F, Xu X, et al. 1,25(OH)2D3 provides protection against diabetic kidney disease by downregulating the TLR4-MyD88-NF-kappaB pathway. Exp Mol Pathol. 2020;114:104434. doi:10.1016/j.yexmp.2020.104434
   PubMedGoogle Scholar
• Cai S, Chen J, Li Y. Dioscin protects against diabetic nephropathy by inhibiting renal inflammation through TLR4/NF-κB pathway in mice. Immunobiology. 2020;225(3):151941. doi:10.1016/j.imbio.2020.151941
   PubMed Web of Science ®Google Scholar
• Ullah MA, Johora FT, Sarkar B, Araf Y, Rahman MH. Curcumin analogs as the inhibitors of TLR4 pathway in inflammation and their drug like potentialities: a computer-based study. J Recept Signal Transduct Res. 2020;1–15. doi:10.1080/10799893.2020.1742741
   Google Scholar
• Lakhia R, Yheskel M, Flaten A, et al. Interstitial microRNA miR-214 attenuates inflammation and polycystic kidney disease progression. JCI Insight. 2020;5(7). doi:10.1172/jci.insight.133785
   PubMedGoogle Scholar
• Shah M, Kim GY, Achek A, et al. The alphaC helix of TIRAP holds therapeutic potential in TLR-mediated autoimmune diseases. Biomaterials. 2020;245:119974. doi:10.1016/j.biomaterials.2020.119974
   PubMedGoogle Scholar
• Yang K, Zhan L, Lu T, et al. Dendrobium officinale polysaccharides protected against ethanol-induced acute liver injury in vivo and in vitro via the TLR4/NF-kappaB signaling pathway. Cytokine. 2020;130:155058. doi:10.1016/j.cyto.2020.155058
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang JH, Liu LL, Li GY, Peng Y, Zhao TJ. Experimental study on growth and reproduction of Tlr4 knockout mice. Chin J Compar Med. 2018;28(12):41–43+50. doi:10.3969/j.issn.1671-7856.2018.12.007
   Google Scholar
• Coenen KR, Gruen ML, Lee-Young RS, Puglisi MJ, Wasserman DH, Hasty AH. Impact of macrophage toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice. Diabetologia. 2009;52(2):318–328. doi:10.1007/s00125-008-1221-7
   PubMedGoogle Scholar
• Lynn M, Rossignol DP, Wheeler JL, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis. 2003;187(4):631–639. doi:10.1086/367990
   PubMed Web of Science ®Google Scholar
• Opal SM, Laterre PF, Francois B, et al. Effect of Eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis the ACCESS randomized trial article. JAMA. 2013;309(11):1154–1162. doi:10.1001/jama.2013.2194
   PubMed Web of Science ®Google Scholar